<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endofocus</journal-id><journal-title-group><journal-title xml:lang="ru">FOCUS Эндокринология</journal-title><trans-title-group xml:lang="en"><trans-title>FOCUS. Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-0177</issn><issn pub-type="epub">2713-0185</issn><publisher><publisher-name>ООО "Издательство "Перо"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/2713-0177-2023-7</article-id><article-id custom-type="edn" pub-id-type="custom">NMSPOV</article-id><article-id custom-type="elpub" pub-id-type="custom">endofocus-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Патология углеводного обмена при первичном гиперпаратиреозе: эпидемиологическая и клиническая характеристика</article-title><trans-title-group xml:lang="en"><trans-title>Pathology of carbohydrate metabolism in primary hyperparathyroidism: epidemiological and clinical characteristics</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5952-5846</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бибик</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Bibik</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>н.с., врач-эндокринолог отделения патологии околощитовидных желез и нарушений минерального обмена</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">bibik.ekaterina@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8916-7346</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Добрева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dobreva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., в.н.с. отделения патологии околощитовидных желез и нарушений минерального обмена</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6667-062X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Еремкина</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Eremkina</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., зав. отделением патологии околощитовидных желез и нарушений минерального обмена</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9717-9742</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мокрышева</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Mokrysheva</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, член-корр. РАН, директор</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ "НМИЦ эндокринологии" Минздрава России</institution></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>05</month><year>2023</year></pub-date><volume>4</volume><issue>1</issue><issue-title>Коморбидность</issue-title><fpage>16</fpage><lpage>22</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бибик Е.Е., Добрева Е.А., Еремкина А.К., Мокрышева Н.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Бибик Е.Е., Добрева Е.А., Еремкина А.К., Мокрышева Н.Г.</copyright-holder><copyright-holder xml:lang="en">Bibik E.E., Dobreva E.A., Eremkina A.K., Mokrysheva N.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://endofocus.elpub.ru/jour/article/view/7">https://endofocus.elpub.ru/jour/article/view/7</self-uri><abstract><p>Первичный гиперпаратиреоз (ПГПТ) характеризуется нарушением не только минерального обмена, но и других звеньев общего метаболизма человека. В связи с повышенной частотой факторов риска сердечно-сосудистой патологии среди больных ПГПТ изучение особенностей нарушений углеводного обмена в данной когорте пациентов позволит разработать оптимальные подходы к их своевременной диагностике и лечению.</p><sec><title>Цель</title><p>Цель. Определить частоту и описать клиническое течение нарушений углеводного обмена у пациентов с ПГПТ.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Проведено одноцентровое ретроспективное исследование взрослых пациентов с ПГПТ с оценкой основных показателей минерального и углеводного обмена до проведения хирургического лечения заболевания. Критериями исключения служили отсутствие ремиссии ПГПТ или рецидив после паратиреоидэктомии в анамнезе; беременность, лактация. Определялась частота различных нарушений углеводного обмена при ПГПТ, сравнительная характеристика показателей минерального обмена при их наличии и отсутствии, а также тяжесть течения сахарного диабета (СД) 2 типа при ПГПТ. Кроме того, исследованы потенциальные взаимосвязи параметров различных видов метаболизма.</p></sec><sec><title>Результаты</title><p>Результаты. Исследование проведено на основании данных историй болезни 367 пациентов с ПГПТ, большинство из которых имели симптомную форму заболевания. Общая частота предиабетических нарушений углеводного обмена составила 4,9% (95% доверительный интервал (ДИ): 3-8). СД 2 типа был ранее диагностирован у 45 пациентов (12%; 95% ДИ: 9-16), случаев впервые выявленного СД не было. У лиц с нарушениями углеводного обмена наблюдались статистически значимо больший индекс массы тела и более низкие значения остеокальцина (27,2 [24,2; 30,4] кг/м2 vs 32,7 [28,1; 39,4] кг/м2 и 48,1 [34; 76,3] нг/мл vs 33,1 [20,8; 51,8] нг/мл, соответственно, для всех параметров р&lt;0,001). Среди больных СД 36 человек (80%) получали сахароснижающую терапию, из них 14 человек — монотерапию метформином и 8 — двухкомпонентную терапию, включая метформин. На инсулинотерапии находились 5 человек. Диабетическая нефропатия диагностирована у 36,4% больных, 15,4% имели признаки диабетической ретинопатии, симптомы диабетической дистальной нейропатии наблюдались у 61,9% пациентов с ПГПТ. Гликемия натощак и показатель гликированного гемоглобина отрицательно коррелировали с показателями костного обмена, а также ожидаемо зависели от фильтрационной функции почек.</p></sec><sec><title>Заключение</title><p>Заключение. Среди пациентов с ПГПТ СД 2 типа встречается чаще, чем в общей популяции. Вероятной причиной этого может являться инсулинорезистентность, в развитии которой не исключается роль метаболитов костного обмена, в первую очередь остеокальцина. В большинстве случаев метформин позволяет достигнуть компенсации СД при ПГПТ.</p></sec></abstract><trans-abstract xml:lang="en"><p>Primary hyperparathyroidism (PHPT) is characterized by disorders of not only mineral metabolism, but also other kinds of the human metabolism. Due to the increased frequency of cardiovascular risk factors among patients with PHPT, the study of the carbohydrate metabolism pathology in this cohort of patients will allow developing optimal approaches to their timely diagnosis and treatment.</p><sec><title>Aim</title><p>Aim. To determine the frequency and describe the clinical features of carbohydrate metabolism disorders in patients with PHPT.</p></sec><sec><title>Material and methods</title><p>Material and methods. A single-center retrospective study of adults with PHPT was carried out with an assessment of the main parameters of mineral and carbohydrate metabolism before surgical treatment of the disease. The exclusion criteria were the absence of PHPT remission or a recurrence of the disease after parathyroidectomy; pregnancy, lactation. The frequency of various disorders of carbohydrate metabolism in PHPT, the comparative characteristics of mineral parameters in patients with and without them, as well as the severity of type 2 diabetes mellitus in PHPT were determined. In addition, potential relationships between the parameters of various types of metabolism have been studied.</p></sec><sec><title>Results</title><p>Results. The study was based on a clinical information of 367 patients with PHPT, most of whom had a symptomatic form of the disease. The overall incidence of prediabetic disorders was 4,9% (95% CI: 3-8). Type 2 diabetes mellitus was previously diagnosed in 45 patients (12%, 95% CI: 9-16), there were no cases of first diagnosed diabetes mellitus. Individuals with impaired carbohydrate metabolism had a statistically significantly higher body mass index and lower values of osteocalcin (27,2 [24,2; 30,4] kg/m2 vs 32,7 [28,1; 39,4 kg/m2 and 48,1 [34; 76,3] ng/mL vs 33,1 [20,8; 51,8] ng/mL, respectively, for all parameters p&lt;0,001). Among patients with type 2 diabetes mellitus, 36 people (80%) took hypoglycemic therapy, 14 of which received metformin monotherapy and 8 received two-component therapy, including metformin. 5 people were on insulin therapy. Diabetic nephropathy was diagnosed in 36,4% of patients, 15,4% had signs of diabetic retinopathy, symptoms of diabetic distal neuropathy were observed in 61,9% of patients with PHPT. Fasting glucose and glycated hemoglobin were negatively correlated with bone metabolism, and also expectedly depended on the glomerular filtration rate.</p></sec><sec><title>Conclusion</title><p>Conclusion. Among patients with PHPT, type 2 diabetes mellitus is more common than in the general population. The likely reason of this may be insulin resistance, that can be caused by the effects of bone metabolites, primarily osteocalcin. In most cases, metformin makes it possible to achieve compensation for diabetes mellitus in PHPT.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>первичный гиперпаратиреоз</kwd><kwd>нарушения углеводного обмена</kwd><kwd>сахарный диабет</kwd><kwd>остеокальцин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>primary hyperparathyroidism</kwd><kwd>carbohydrate metabolism disorders</kwd><kwd>diabetes mellitus</kwd><kwd>osteocalcin</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено при финансовой поддержке Министерства здравоохранения Российской Федерации в рамках выполнения государственного задания "Оптимизация Российского электронного реестра пациентов с первичным гиперпаратиреозом" № НИОКТР 121030100032-7.</funding-statement><funding-statement xml:lang="en">The study was carried out with the financial support of the Ministry of Health of the Russian Federation as part of the state task “Optimization of the Russian electronic register of patients with primary hyperparathyroidism” project number НИОКТР 121030100032-7.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Axelsson KF, Wallander M, Johansson H, et al. Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. JAMA Netw open. 2022;5(6):e2215396. doi:10.1001/jamanetworkopen.2022.15396.</mixed-citation><mixed-citation xml:lang="en">Axelsson KF, Wallander M, Johansson H, et al. Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. JAMA Netw open. 2022;5(6):e2215396. doi:10.1001/jamanetworkopen.2022.15396.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Corbetta S, Mantovani G, Spada A. Metabolic Syndrome in Parathyroid Diseases. Front Horm Res. 2018;49:67-84. doi:10.1159/000486003.</mixed-citation><mixed-citation xml:lang="en">Corbetta S, Mantovani G, Spada A. Metabolic Syndrome in Parathyroid Diseases. Front Horm Res. 2018;49:67-84. doi:10.1159/000486003.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мокрышева Н. Г., Добрева Е. А., Мирная С. С., Дедов И. И. Нарушения углеводного и жирового обмена у женщин с первичным гиперпаратиреозом: результаты поперечного исследования. Сахарный диабет. 2019;22(1):8-13. doi:10.14341/DM9450.</mixed-citation><mixed-citation xml:lang="en">Mokrysheva NG, Dobreva EA, Mirnaya SS, Dedov II. Carbohydrate and lipid metabolism disorders in women with primary hyperparathyroidism: results of cross-sectional study. Diabetes mellitus. 2019;22(1):8-13. (In Russ.) doi:10.14341/DM9450.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Бибик Е. Е., Еремкина А. К., Крупинова Ю. А. и др. Нарушения углеводного обмена и другие метаболические изменения при первичном гиперпаратиреозе. Сахарный диабет. 2020;23(5):459-66. doi:10.14341/DM12436.</mixed-citation><mixed-citation xml:lang="en">Bibik EE, Eremkina AK, Krupinova JA, et al. Impaired glucose metabolism and other metabolic disorders in patients with primary hyperparathyroidism. Diabetes Mellitus. 2021;23(5):459-66. (In Russ.) doi:10.14341/DM12436.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Бибик Е. Е., Добрева Е. А., Айнетдинова А. Р. и др. Метаболический профиль пациентов молодого возраста с первичным гиперпаратиреозом. Ожирение и метаболизм. 2021;18(3):236-44. doi:10.14341/omet12771.</mixed-citation><mixed-citation xml:lang="en">Bibik EE, Dobreva EA, Ajnetdinova AR, et al. Metabolic features of young patients with primary hyperparathyroidism. Obesity and metabolism. 2021;18(3):236-44. (In Russ.) doi:10.14341/omet12771.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cvijovic G, Micic D, Kendereski A, et al. The effect of parathyroidectomy on insulin sensitivity in patients with primary hyperparathyroidism — an never ending story? Exp Clin Endocrinol Diabetes. 2015;123(6):336-41. doi:10.1055/s-0035-1549906.</mixed-citation><mixed-citation xml:lang="en">Cvijovic G, Micic D, Kendereski A, et al. The effect of parathyroidectomy on insulin sensitivity in patients with primary hyperparathyroidism — an never ending story? Exp Clin Endocrinol Diabetes. 2015;123(6):336-41. doi:10.1055/s-0035-1549906.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gianotti L, Piovesan A, Croce CG, et al. Interplay between serum osteocalcin and insulin sensitivity in primary hyperparathyroidism. Calcif Tissue Int. 2011;88(3):231-7. doi:10.1007/s00223-010-9453-1.</mixed-citation><mixed-citation xml:lang="en">Gianotti L, Piovesan A, Croce CG, et al. Interplay between serum osteocalcin and insulin sensitivity in primary hyperparathyroidism. Calcif Tissue Int. 2011;88(3):231-7. doi:10.1007/s00223-010-9453-1.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Karras SN, Koufakis T, Tsekmekidou X, et al. Increased parathyroid hormone is associated with higher fasting glucose in individuals with normocalcemic primary hyperparathyroidism and prediabetes: A pilot study. Diabetes Res Clin Pract. 2020;160:107985. doi:10.1016/j.diabres.2019.107985.</mixed-citation><mixed-citation xml:lang="en">Karras SN, Koufakis T, Tsekmekidou X, et al. Increased parathyroid hormone is associated with higher fasting glucose in individuals with normocalcemic primary hyperparathyroidism and prediabetes: A pilot study. Diabetes Res Clin Pract. 2020;160:107985. doi:10.1016/j.diabres.2019.107985.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sun G, Vasdev S, Martin GR, et al. Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and beta-cell function in the Newfoundland population. Diabetes. 2005;54(11):3336-9. doi:10.2337/diabetes.54.11.3336.</mixed-citation><mixed-citation xml:lang="en">Sun G, Vasdev S, Martin GR, et al. Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and beta-cell function in the Newfoundland population. Diabetes. 2005;54(11):3336-9. doi:10.2337/diabetes.54.11.3336.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Мокрышева Н. Г., Еремкина А. К., Мирная С. С. и др. Клинические рекомендации по первичному гиперпаратиреозу, краткая версия. Проблемы Эндокринологии. 2021;67(4):94-124. doi:10.14341/probl12801.</mixed-citation><mixed-citation xml:lang="en">Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. (In Russ.) doi:10.14341/probl12801.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И. И., Шестакова М. В., Майоров А. Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2021;24(1S):1-148. doi:10.14341/DM12802.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Mayorov AYu. Standards of specialized diabetes care. Edited by Dedov I. I., Shestakova M. V., Mayorov A. Yu. 10th edition. Diabetes mellitus. 2021;24(1S):1-148. (In Russ.) doi:10.14341/DM12802.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И. И., Шестакова М. В., Галстян Г. Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12. doi:10.14341/DM2004116-17.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104-12. (In Russ.) doi:10.14341/DM2004116-17.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Procopio M, Barale M, Bertaina S, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47(2):581-9. doi:10.1007/s12020-013-0091-z.</mixed-citation><mixed-citation xml:lang="en">Procopio M, Barale M, Bertaina S, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47(2):581-9. doi:10.1007/s12020-013-0091-z.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kanazawa I. Interaction between bone and glucose metabolism [Review]. Endocr J. 2017;64(11):1043-53. doi:10.1507/endocrj.EJ17-0323.</mixed-citation><mixed-citation xml:lang="en">Kanazawa I. Interaction between bone and glucose metabolism [Review]. Endocr J. 2017;64(11):1043-53. doi:10.1507/endocrj.EJ17-0323.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bao Y, Ma X, Yang R, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab. 2013;98(1):345-51. doi:10.1210/jc.2012-2906.</mixed-citation><mixed-citation xml:lang="en">Bao Y, Ma X, Yang R, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab. 2013;98(1):345-51. doi:10.1210/jc.2012-2906.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008;105(13):5266-70. doi:10.1073/pnas.0711119105.</mixed-citation><mixed-citation xml:lang="en">Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008;105(13):5266-70. doi:10.1073/pnas.0711119105.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Guedes JAC, Esteves J V, Morais MR, et al. Osteocalcin improves insulin resistance and inflammation in obese mice: Participation of white adipose tissue and bone. Bone [Internet]. 2018;115:68-82. doi:10.1016/j.bone.2017.11.020.</mixed-citation><mixed-citation xml:lang="en">Guedes JAC, Esteves J V, Morais MR, et al. Osteocalcin improves insulin resistance and inflammation in obese mice: Participation of white adipose tissue and bone. Bone [Internet]. 2018;115:68-82. doi:10.1016/j.bone.2017.11.020.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wei J, Ferron M, Clarke CJ, et al. Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest [Internet]. 2014;124(4):1781-93. doi:10.1172/JCI72323.</mixed-citation><mixed-citation xml:lang="en">Wei J, Ferron M, Clarke CJ, et al. Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest [Internet]. 2014;124(4):1781-93. doi:10.1172/JCI72323.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Bilotta FL, Arcidiacono B, Messineo S, et al. Insulin and osteocalcin: further evidence for a mutual cross-talk. Endocrine [Internet]. 2018;59(3):622-32. doi:10.1007/s12020-017-1396-0.</mixed-citation><mixed-citation xml:lang="en">Bilotta FL, Arcidiacono B, Messineo S, et al. Insulin and osteocalcin: further evidence for a mutual cross-talk. Endocrine [Internet]. 2018;59(3):622-32. doi:10.1007/s12020-017-1396-0.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J-M, Rosen CJ, Ducy P, et al. Regulation of Glucose Handling by the Skeleton: Insights From Mouse and Human Studies. Diabetes. 2016;65(11):3225-32. doi:10.2337/db16-0053.</mixed-citation><mixed-citation xml:lang="en">Liu J-M, Rosen CJ, Ducy P, et al. Regulation of Glucose Handling by the Skeleton: Insights From Mouse and Human Studies. Diabetes. 2016;65(11):3225-32. doi:10.2337/db16-0053.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И. И., Шестакова М. В., Майоров А. Ю. и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4-102. doi:10.14341/DM12507.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020;23(2S):4-102. (In Russ.) doi:10.14341/DM12507.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Tassone F, Procopio M, Gianotti L, et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet Med. 2009;26(10):968-73. doi:10.1111/j.1464-5491.2009.02804.x.</mixed-citation><mixed-citation xml:lang="en">Tassone F, Procopio M, Gianotti L, et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet Med. 2009;26(10):968-73. doi:10.1111/j.1464-5491.2009.02804.x.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
